Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a medical injectable drug program

Journal of Managed Care Pharmacy

Volumn 17, Issue 1, 2011, Pages 51-59

  Baldini, Christopher G ^a   Culley, Eric J ^a  

^a Clinical Pharmacy Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; AGALSIDASE BETA; ALEFACEPT; BACLOFEN; BETA1A INTERFERON; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CETRORELIX; EFALIZUMAB; ETANERCEPT; GAMMA1B INTERFERON; GANIRELIX; GLATIRAMER; HUMAN MENOPAUSAL GONADOTROPIN; HYALURONIC ACID; IMIGLUCERASE; INFLIXIMAB; INTERFERON BETA SERINE; LARONIDASE; LEUPRORELIN; OMALIZUMAB; OMEGA CONOTOXIN MVIIA; PALIVIZUMAB; PEGAPTANIB; PRESCRIPTION DRUG; RECOMBINANT FOLLITROPIN; RECOMBINANT THYROTROPIN; RISPERIDONE; SOMATREM; UNINDEXED DRUG; UROFOLLITROPIN; VERTEPORFIN;

ARTICLE; CLINICAL EVALUATION; COST CONTROL; DRUG CONTROL; DRUG COST; DRUG MANUFACTURE; HEALTH PROGRAM; MANAGED CARE ORGANIZATION; MEDICAL INJECTABLE DRUG PROGRAM; PHARMACY;

EID: 78650854327     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.1.51     Document Type: Article

References (16)

1. Kaiser Family Foundation. U.S. health care costs. Background brief. March 2010. Available at: http://www.kaiseredu.org/topics_im.asp?imID=1&parentID=61&id=358. Accessed December 17, 2010.
2. Express Scripts. 2009 drug trend report. April 2010. Available at: http://www.express-scripts.com/research/studies/drugtrendreport/2009/dtrFinal.pdf. Accessed December 17, 2010.
3. Medco. 2008 drug trend report. Available at: http://medco.mediaroom.com/file.php/162/2008+DRUG+TREND+REPORT.pdf. Accessed December 17, 2010.
4. Medco. 2009 drug trend report. Available at: http://medco.mediaroom.com/file.php/177/2009+DRUG+TREND+REPORT.pdf. Accessed December 17, 2010
5. Cohen M, Morrow T, Penna P. Managing the expanded use of biologics across therapeutic areas: an example from B-cell targeted therapies. Am J Manag Care. 2006;12(2 Suppl):S24-S37. Available at: http://www.ajmc.com/media/pdf/A150_06mar_CohenS24toS37.pdf. Accessed December 17, 2010.
6. Stern D. Benefit design innovations to manage specialty pharmaceuticals. J Manag Care Pharm. 2008;14(4 Suppl):S12-S16. Available at: http://www.amcp.org/data/jmcp/JMCPSupp_S12-S16.pdf.
7. Nagle PC, Nicita CA, Gerdes LA, Schmeichel CJ. Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am J Manag Care. 2008;14(4):226-29. Available at: http://www.ajmc.com/media/pdf/AJMC_08apr_Nagle_226to29.pdf. Accessed December 17, 2010.
8. Walgreens Specialty Pharmacy. Outlook: state of the industry report 2009. Available at: http://www.walgreensmail.com/pdf/newsletterreport/SOIReport2009.pdf. Accessed December 17, 2010.
9. Keehan S, Sisko A, Truffer C, et al. Health spending projections through 2017: the baby-boom generation is coming to Medicare. Health Aff (Millwood). 2008;27(2):w145-55. Epub 2008 Feb 26.
10. Sullivan SD. The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm. 2008;14(4 Suppl):S3-S6. Available at: http://www.amcp.org/data/jmcp/JMCPSupp_S3-S6.pdf.
11. McDonald RC. Managing the intersection of medical and pharmacy benefits. J Manag Care Pharm. 2008;14(4 Suppl):S7-S11. Available at: http://www.amcp.org/data/jmcp/JMCPSupp_S7-S11.pdf.
12. Mullins CD, DeVries AR, Hsu VD, Meng F, Palumbo FB. Variability and growth in spending for outpatient specialty pharmaceuticals. Health Aff (Millwood). 2005;24(4):1117-27.
13. EMD Serono. EMD Serono injectables digest. 5th edition. April 2009. Available at: https://olr.dwainc.com/2559Digest/PDF/EMDSerono5thEditionInjectablesDigest.pdf. Accessed December 17, 2010
14. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm. 2006;12(9):736-44. Available at: http://www.amcp.org/data/jmcp/736-744.pdf.
15. Serono. Serono Injectables Digest. 2nd edition. Rockland, MA: Serono; 2006.
16. Jacobson M, Earle CC, Price M, Newhouse JP. How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood). 2010;29(7):1391-99.